BioCity Biopharma’s selective endothelin receptor type A (ETA) antagonist has reduced excess proteins in the urine of patients with diabetic kidney disease (DKD), hitting a primary endpoint of a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback